Press Releases
Cell Signaling Technology (CST) press releases are grouped by year and linked below.
2013
2012
- Cell Signaling Technology, Inc. Announces Novel Discovery Platform for Isolation of High-affinity Antigen-specific Monoclonal Antibodies Directly from Human Serum | Dec 5
- Cell Signaling Technology, Inc. Develops Novel Monoclonal Antibody Discovery Platform | May 10
- Ventana to collaborate with Pfizer and Cell Signaling Technology, Inc. on companion diagnostic to identify lung cancer patients with ALK gene rearrangements | January 9
2011
- Cell Signaling Technology, Inc. wins Life Science Industry Awards in “Best Performing Antibodies” and “Best Breakthrough Products Cancer Research” Categories | December 5
- Cell Signaling Technology, Inc. Grants a Patent License to Pfizer | July 5
- Cell Signaling Technology, Inc. Announces License in Personalized Cancer Diagnostics | March 14
- Cell Signaling Technology, Inc. Announces Joint Commercialization Partnership with Astellas Pharma in Cancer Personalized Medicine | February 23
2009
2008
- Cell Signaling Technology, Inc. Announces Renewal of PhosphoScan® Proteomics Research Project for Lead Compound Biomarker Discovery | Nov 6
- Cell Signaling Technology, Inc. Donation to Beverly High | June 18
- Cell Signaling Technology, Inc. Expands Operations Overseas | April 8
- CST Announces Continued Collaboration with AstraZeneca to Provide CST’s PhosphoScan® Platform for Kinase Inhibitor Proteomic Profiling | February 12
- CST Announces Continued PhosphoScan® Proteomics Research Project with Bristol-Myers Squibb for Kinase Inhibitor Profiling | February 5
- CST and TTP LabTech Collaborate to Develop and Co-Market Antibodies and Acumen® Cytometric Assay Solutions for High Content Screening and Drug Discovery | January 31
2007
- CST Goes Green. | November 8
- CST Announces PhosphoScan® Profiling Technology & PhosphoSite® Knowledgebase | October 31
- CST Expands its PhosphoScan® Patent Portfolio | March 27
- CST Announces Alliance with Merck to Provide PhosphoScan® Proteomics & Antibody Development | March 27
2006
- CST Announces Alliance with AstraZeneca to Provide Rabbit Monoclonal Technologies | December 20
- CST Announces a Research Project with Bristol-Myers Squibb Company | December 5
- CST Demonstrates the Discovery Capabilities of its PhosphoScan® Proteomics Platform | August 3
- CST Expands Partnership with Bio-Rad to Develop Phosphoprotein Assays | June 6
- CST Continues Collaboration with AstraZeneca to Provide CST's PhosphoScan® Platform | April 12
- CST Announces Expansion of Studies with AstraZeneca to Evaluate CST's PhosphoScan® Platform | January 9
2005
- CST Announces Pilot Study to Evaluate CST's PhosphoScan® Platform | August 1
- CST Announces Pilot Study for Chiron Corporation | May 31
2004
- CST Announces Pilot Study for Aventis | September 20
- CST Announces Partnership with AstraZeneca to Identify Biomarkers | June 12
- CST and LI-COR Biosciences, Inc. Joint Marketing Agreement | June 1
- CST and Zeptosens AG Antibody Agreement | April 19
- CST and ProQinase GmbH Drug Discovery Partnership | March 22
2003
- CST Launches PhosphoSite® Database | November 17
- CST Launches SignalSilence® siRNA Kits | November 17
- ACLARA and CST Antibody Agreement | November 17
- Dana-Farber, Phosphoproteomics, and CST Phospho-Peptide Agreement | October 23
- Bio-Rad and CST Research, Supply and Co-Marketing Agreement | August 26
- CST and Beckman Coulter, Inc. Co-Development Co-Marketing Agreement | February 20
2002
- CST Patents Novel “Motif Antibody” Technology | October 22
- CST and Alliance for Cellular Signaling Collaboration | January 9
